RMD

RMD

USD

ResMed Inc. Common Stock

$235.880-2.680 (-1.123%)

Precio en Tiempo Real

Healthcare
Medical Instruments & Supplies
Estados Unidos

Gráfico de Precios

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$238.560

Máximo

$238.940

Mínimo

$230.510

Volumen

0.18M

Fundamentos de la Empresa

Capitalización de Mercado

34.6B

Industria

Medical Instruments & Supplies

País

United States

Estadísticas de Negociación

Volumen Promedio

1.14M

Bolsa

NYQ

Moneda

USD

Rango de 52 Semanas

Mínimo $179.42Actual $235.880Máximo $263.05

Informe de Análisis de IA

Última actualización: 24 abr 2025
Generado por IAFuente de Datos: Yahoo Finance, Bloomberg, SEC

RMD: ResMed Inc. Common Stock - Breaking Down Recent Performance and What's Next

Stock Symbol: RMD Generate Date: 2025-04-24 11:08:14

Alright, let's take a look at what's been happening with ResMed, the company known for its sleep and respiratory tech. We've got some fresh news, a peek at the recent stock chart, and even some AI predictions to chew on.

Recent News Buzz: The Vibe is Mostly Upbeat

The biggest piece of news just hit: ResMed announced its results for the third quarter of fiscal year 2025. And honestly? The numbers look pretty solid. Revenue climbed 8% compared to the same time last year. Operating profit jumped even more, up 14%, and the non-GAAP version (which often smooths out certain costs) was up a healthy 13%. Plus, they pulled in a hefty $579 million in operating cash flow. That's the kind of stuff investors generally like to see – the business is growing and making money efficiently.

There was also news about a new Chief Investor Relations Officer coming aboard. That's standard corporate stuff, probably not a major market mover on its own.

A slightly mixed signal came from Keybanc, an investment bank. They kept their "Overweight" rating on ResMed, which is still a positive view, suggesting they think the stock will do better than the average in its sector. However, they did trim their price target a bit, lowering it from $280 to $269. So, while they still like the stock, maybe they're seeing slightly less explosive upside than before, or just adjusting based on market conditions.

Putting it together, the vibe from the news is definitely leaning positive, thanks to those strong earnings numbers. The analyst's slightly lower target is a minor note in the background compared to the actual financial performance reported.

Price Check: A Recent Bounce After a Slide

Looking at the stock's journey over the last month or two, it's been a bit of a bumpy ride. After trading in the $240s and $250s earlier in the year, the price drifted lower, dipping significantly in early April, even touching down near the $200 mark.

More recently, though, it seems to have found some footing and bounced back a bit, trading in the $210-$215 range. The last trading day (April 23rd) saw some volatility, hitting a high above $221 before closing back around $214. This kind of intraday swing can sometimes happen right before or after big news like earnings.

Now, let's peek at the AI's crystal ball. The AI model is predicting positive movement starting today. It forecasts a 2.55% gain today, another 2.50% tomorrow, and a 3.17% jump the day after. These predictions suggest the AI expects the stock to react positively to that strong earnings report we just discussed.

Comparing the recent price action (a bounce off lows) with the AI's forecast (upward trend), it seems the AI believes the positive news will override the prior downward momentum.

Outlook & Ideas: Riding the Earnings Wave?

Based on the strong earnings report and the AI's optimistic forecast for the next few days, the near-term situation for RMD seems to favor potential buyers. The company is showing solid growth and profitability, which is the fundamental engine for stock value. The AI model is clearly picking up on this positive signal and projecting an upward move.

So, what might someone considering this stock think about?

  • Potential Entry Consideration: If you're looking at getting in, the current price area, perhaps around the previous day's close of $214.08 or slightly higher if it opens strong today, could be a point to consider. The AI's prediction of upward movement starting today aligns with this. The recommendation data even suggested entry points slightly above the last close ($215.94, $217.25), anticipating a move up.
  • Potential Exit/Stop-Loss Consideration: Managing risk is always key. The recommendation data suggests a stop-loss level around $192.89. This is well below recent lows and could serve as a point to exit if the stock unexpectedly reverses course and breaks down significantly. On the upside, the AI projects a potential target around $251.24, and the analyst consensus target is even higher at $265.42. These levels could be considered potential areas to take profits if the stock makes a strong move up, though hitting them isn't guaranteed.

Remember, this is just interpreting the data provided. The market can be unpredictable.

Company Context: Healthcare Tech in Focus

It's helpful to remember that ResMed operates in the healthcare sector, specifically focusing on technology for sleep, breathing, and home care. This means their performance is tied to trends in those areas, like the growing need for sleep apnea treatments and home-based healthcare solutions. The strong earnings growth we saw is a direct reflection of success in this market.

While the company has a decent P/E ratio and good Return on Equity, the recommendation data did flag high debt and growth that was perhaps lower than some expectations (though 8% revenue growth is still respectable). These are factors to keep in mind, but the recent earnings report seems to be the dominant positive driver right now. The fact that 15 analysts have a strong buy rating with a high average target price also adds weight to the positive outlook from the professional community.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock investing involves risk, and you could lose money. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Noticias Relacionadas

Analyst Upgrades

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $255

RBC Capital analyst Craig Wong-Pan maintains ResMed with a Sector Perform and raises the price target from $247 to $255.

Ver más
RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $255
Analyst Upgrades

JP Morgan Maintains Overweight on ResMed, Raises Price Target to $290

JP Morgan analyst David Low maintains ResMed with a Overweight and raises the price target from $286 to $290.

Ver más
JP Morgan Maintains Overweight on ResMed, Raises Price Target to $290
Analyst Upgrades

Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $248

Piper Sandler analyst Adam Maeder maintains ResMed with a Neutral and lowers the price target from $260 to $248.

Ver más
Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $248
Analyst Upgrades

Keybanc Maintains Overweight on ResMed, Raises Price Target to $274

Keybanc analyst Brett Fishbin maintains ResMed with a Overweight and raises the price target from $269 to $274.

Ver más
Keybanc Maintains Overweight on ResMed, Raises Price Target to $274
GlobeNewswire

Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025

Year-over-year revenue grows 8%, operating profit up 14%, non-GAAP operating profit up 13%Operating cash flow of $579 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today

Ver más
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2025
GlobeNewswire

Resmed Names Salli Schwartz as Chief Investor Relations Officer

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment

Analyst Upgrades

Keybanc Maintains Overweight on ResMed, Lowers Price Target to $269

Keybanc analyst Tim Rezvan maintains ResMed with a Overweight and lowers the price target from $280 to $269.

Predicción de IABeta

Recomendación de IA

Alcista

Actualizado el: 27 abr 2025, 18:20

BajistaNeutralAlcista

75.9% Confianza

Riesgo y Negociación

Nivel de Riesgo1/5
Riesgo Bajo
Adecuado Para
Conservador
Guía de Negociación

Punto de Entrada

$235.22

Toma de Ganancias

$250.70

Stop Loss

$212.20

Factores Clave

PDI 8.0 está por encima de MDI 3.7 con ADX 16.1, lo que sugiere una tendencia alcista
El precio actual está extremadamente cerca del nivel de soporte ($234.41), lo que sugiere una fuerte oportunidad de compra
El volumen de operaciones es 10.9 veces el promedio (11,183), lo que indica una presión de compra extremadamente fuerte
El MACD 0.4276 está por encima de la línea de señal 0.2488, lo que indica un cruce alcista

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.